dublin, March 15, 2024 /PRNewswire/ — “Digital Marketing Trends in Non-Small Cell Lung Cancer” report added ResearchAndMarkets.com Recruitment.
Merck's Keytruda.com achieved the highest total traffic of any non-small cell lung cancer (NSCLC) patient site in the United States, with more than 2.4 million visitors from the United States. October 2022 to September 2023. It was followed by BMS' Opdivo.com (1.7 million visits) and AstraZeneca's Imfinzi.com (350,000 visits). Keytruda.com is also supported by the most paid search engine optimization (SEO) with over 7,600 keywords, closely followed by Enhertu.com (6,640) and Opdivo.com (5,840). Ta.
Overall, the highest percentage of traffic to top brand patient NSCLC websites came from direct and organic sources. His Imfinzihcp.com for AstraZeneca achieved the highest total traffic of all his NSCLC HCP sites in the US, with approximately 300,000 visitors from the US. October 2022 to September 2023.
This was followed by Merck's Keytrudahcp.com (approximately 230,000 visits). Overall, the highest percentage of traffic to branded NSCLC websites for healthcare professionals comes from direct sources, followed by paid traffic and organic traffic. Imfinzihcp.com is the most paid SEO favored with 7,167 keywords, closely followed by Lumakrashcp.com (7,159) and his Enhertuhcp.com (7,018).
Merck's Undercancertogether.com achieved the highest total traffic of all U.S. NSCLC non-branded sites, with 94,000 visitors from: October 2022 to September 2023, followed by Pfizer's Thisislivingwithcancer.com (7,500 views). Merck spent the most on his DDA on Understandcancertogether.com. $94,000.
DDA was also detected for Thisislivingwithcancer.com ($8,000). Thisislivingwithcancer.com is supported by the most paid SEO with over 2,170 keywords, followed closely by Understandcancertogether.com with over 2,000 keywords. No traffic to EUCAN branded NSCLC sites detected.
Roche's Daskwort.de achieved the highest total traffic across EUCAN's NSCLC non-branded sites, with approximately 350,000 visitors. October 2022 to September 2023, followed by Pfizer's Pactonco.fr (130,000 views). Overall, the highest percentage of unbranded website traffic came from organic sources, followed by direct. No DDA spending or SEO of his was detected on these sites.
range
- This report evaluates key digital marketing metrics for NSCLC pharmaceutical assets, including branded websites, unbranded websites, and social media accounts for patients and healthcare professionals.
- Metrics include website traffic volume, engagement, sources, DDA, paid SEO, and social media post interactions.
- Countries include the US, 4EU (Italy, France, Germanyand Spain), UK, and Canada (U-Can).
Reasons to buy
- Understand the competitive landscape for digital marketing in NSCLC from the perspective of key patient and provider brand assets across different geographies.
- See what tactics pharmaceutical companies are using to drive traffic to their NSCLC brand assets for patients and healthcare professionals, including DDA and paid SEO.
- Understand the sources of your website's traffic, such as paid SEO, social media, and organic search, are generating the most visits to these assets.
- Compare the top branded and unbranded assets for patients by how they address and support different patient needs.
- See which pharma social media accounts are the most active and achieve the most engagement on PsO.
Main topics covered:
- executive summary
- US branded site for patients
- US-branded website for healthcare professionals
- US unbranded sites
- EUCAN unbranded website
- appendix
Some of the companies mentioned in this report include:
- Merck
- BMS
- AstraZeneca
- pfizer
- regeneron
- Roche
For more information on this report, please visit https://www.researchandmarkets.com/r/q1qrj9.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
Media contact:
research and market
Laura WoodSenior Manager
[email protected]
For Eastern Standard Time office hours, please call +1-917-300-0470.
For USA/Canada Toll Free +1-800-526-8630
For GMT office hours, please call +353-1-416-8900.
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Source Research and Market
